NCT05205044

Brief Summary

Lower Apelin levels are associated with hypertensive disorders with pregnancy, yet no studies investigated its levels in recurrent pregnancy loss

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
88

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2022

Shorter than P25 for all trials

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 11, 2022

Completed
12 days until next milestone

Study Start

First participant enrolled

January 23, 2022

Completed
1 day until next milestone

First Posted

Study publicly available on registry

January 24, 2022

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 30, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 30, 2023

Completed
Last Updated

February 14, 2023

Status Verified

February 1, 2023

Enrollment Period

1 year

First QC Date

January 11, 2022

Last Update Submit

February 12, 2023

Conditions

Recurrent Pregnancy Loss

Outcome Measures

Primary Outcomes (1)

  • Apelin-13 and Apelin-36

    Serum levels of Apelin-13 and Apelin-36

    1 year

Study Arms (2)

Recurrent pregnancy loss

Diagnostic Test: Apelin-13, Apelin-36

Healthy

Diagnostic Test: Apelin-13, Apelin-36

Interventions

Apelin-13, Apelin-36DIAGNOSTIC_TEST

Serum levels of Apelin-13 and Apelin-36

HealthyRecurrent pregnancy loss

Eligibility Criteria

Age18 Years - 40 Years
Sexfemale(Gender-based eligibility)
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Pregnant females in first trimester

You may qualify if:

  • pregnant women in first trimester
  • negative antiphospholipid markers
  • normal karyotype

You may not qualify if:

  • multiple pregnancy
  • fetal malformations
  • maternal diseases
  • smoking or alcohol use
  • history of or risk factors for preterm labor

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Ain Shams University Maternity Hospital

Cairo, Cairo/القاهرة, 71350, Egypt

Location

AinShams Maternity Hospital

Cairo, 002, Egypt

Location

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 11, 2022

First Posted

January 24, 2022

Study Start

January 23, 2022

Primary Completion

January 30, 2023

Study Completion

January 30, 2023

Last Updated

February 14, 2023

Record last verified: 2023-02

Locations

EG(2)